Doxycycline in Type II Diabetes
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insu
| Condition(s) | Diabetes Mellitus, Type 2 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden |
| Who can participate | Inclusion Criteria: * Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5 Exclusion Criteria: * Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation |
| Ages | 40 Years to 60 Years |
| Sex | All |
| Lead sponsor | Mostafa Bahaa |
| Locations | Tanta, Egypt |
| Start date | 2024-03-30 |
| NCT ID | NCT06329882 |
| Official listing | https://clinicaltrials.gov/study/NCT06329882 |